Vigil Neuroscience Inc. (VIGL)
1.89
0.11 (6.18%)
At close: Jan 15, 2025, 12:31 PM
undefined% (undefined)
| Bid | 1.87 |
| Market Cap | 77.25M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.07 |
| PE Ratio (ttm) | -0.91 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.89 |
| Volume | 82,347 |
| Avg. Volume (20D) | 240,950 |
| Open | 1.82 |
| Previous Close | 1.78 |
| Day's Range | 1.80 - 1.95 |
| 52-Week Range | 1.49 - 6.06 |
| Beta | undefined |
About VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy wi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 64
Stock Exchange NASDAQ
Ticker Symbol VIGL
Website https://www.vigilneuro.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 931.86% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 months ago ·
Source
-10.02%
Vigil Neuroscience shares are trading lower. The c...
Unlock content with
Pro Subscription
6 months ago ·
Source
+18.52%
Vigil Neuroscience shares are trading higher after Sanofi made a $40 million investment in the company.
